Form 8-K - Current report:
SEC Accession No. 0001193125-21-307134
Filing Date
2021-10-26
Accepted
2021-10-26 06:08:58
Documents
13
Period of Report
2021-10-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d164687d8k.htm   iXBRL 8-K 31037
2 EX-99.1 d164687dex991.htm EX-99.1 6335
  Complete submission text file 0001193125-21-307134.txt   160729

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20211023.xsd EX-101.SCH 2884
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20211023_lab.xml EX-101.LAB 17375
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20211023_pre.xml EX-101.PRE 10948
6 EXTRACTED XBRL INSTANCE DOCUMENT d164687d8k_htm.xml XML 3205
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 211345839
SIC: 2834 Pharmaceutical Preparations